Navigation Links
NPS Pharmaceuticals Reports 2007 Financial Results
Date:3/13/2008

ch and development expenses during 2007 was attributable to the implementation of the company's new business plan and the corresponding reprioritization of its pipeline to focus on specialty indications with high unmet medical need.

General and Administrative

NPS's fourth quarter general and administrative expenses were $9.3 million versus $9.8 million for the fourth quarter of 2006. Full-year general and administrative expenses were $27.0 million for 2007 as compared to $52.2 million for 2006. The declines in general and administrative expenses were attributable to reductions in personnel and associated expenditures due to the implementation of the company's new business plan.

Restructuring Charges

NPS reported restructuring chares of $1.1 million for the fourth quarter of 2007 as compared to a $61,000 credit for the fourth quarter of 2006. For the full year, restructuring charges for 2007 were $13.4 million versus $8.2 million in 2006. Restructuring charges were primarily comprised of employee termination benefits.

Gain on sale of asset

In connection with the implementation of NPS's new business plan, the company sold its interests in an early-stage research and development collaboration with AstraZeneca for metabotropic glutamate receptors (mGluRs) and recognized a $30.0 million gain in the fourth quarter of 2007.

Cash and Investments

As of December 31, 2007, the company's cash, cash equivalents, short- and long-term investments totaled $161.7 million, as compared to $146.2 million as of December 31, 2006.

The company's investment portfolio includes investments in certain auction-rate securities or ARS investments. As of December 31, 2007, the company's ARS investments had an estimated value of $53.3 million and a cost basis of $59.8 million.

Recently, NPS agreed to sell certain of these ARS investments to one of its investment advisors for $26.0 million. These securities had an estimated marke
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
2. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
3. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
4. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
5. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
8. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
9. Onyx Pharmaceuticals to Present at Cowen and Company Health Care Conference
10. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
11. VIA Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... The Fertility Centers of New England ... Vitiello has taken on a new and expanded role ... provide guidance, leadership, oversight and quality assurance for the ... among our team of experienced reproductive endocrinologists,” said Fertility ... Hill, M.D. “Her expertise and compassionate, individualized care have ...
(Date:5/28/2015)... Dr. Carl Peck, MD, Chairman of ... Williams, MD, has joined the firm as a ... top tier consultants whose expertise and professional stature ... company’s clients. Premier Experts collaborate to design and ... their medical products, pursue optimal regulatory pathways, build ...
(Date:5/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/l633xp/molecular ... PharmaBiotech,s new report "Molecular Diagnostics - ... offering. This report describes and ... play an important role in practice of ... biological warfare in the 21st century. This ...
(Date:5/27/2015)... , May 27, 2015  Tikcro Technologies Ltd. (OTCQB: ... March 31, 2015. Aviv Boim ... continued pre-clinical work to generate functional specific antibodies, targeting ... stage, we are encouraged by the development progress. We ... new antibodies which modulate immune checkpoints gain clinical acceptance ...
Breaking Biology Technology:Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3
... Wound Management Technologies, Inc., (OTC Bulletin Board: ... announced today that its President, Deborah Jenkins Hutchinson, will ... CellerateRX®, recent strategic developments, and its product pipeline at ... held at the JW Marriott Marquis Miami on November ...
... Accuray Incorporated (Nasdaq: ARAY ), a global ... management is scheduled to present at the Lazard Capital Markets, ... 2010 at 10:30 a.m. ET/7:30 a.m. PT. A ... the Investor Relations page of the Company,s Web site at ...
... , University of California, Berkeley, scientists have found a way ... the poor resolution of the picture. Everyone who ... with the impressionistic nature of the images. One of the ... of the sound: The basic laws of physics dictate that ...
Cached Biology Technology:Wound Management Technologies to Present at LifeTech Capital Miami Medical Investors Conference 2Accuray Incorporated to Speak at Seventh Annual Lazard Capital Markets' Healthcare Conference 2Novel metamaterial vastly improves quality of ultrasound imaging 2
(Date:4/27/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... the first week of May, 2015 and will be ... Gino Pereira , Chief Executive ... company as Wocket® enters the consumer market. We would ...
(Date:4/21/2015)... , April 21, 2015 ... evolving government policies are boosting access control systems market ... According to a recently published report by TechSci ... 2020 ", the access control systems market in ... USD1.2 billion by 2020.The access control systems market in ...
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... co-operation with a research group from Singapore, scientists at ... in the form of truncated O-glycans aid growth properties ... to decode the significance of these truncated O-glycans, and ... journal PNAS , represent an important contribution to ...
... our brains how full we are becomes damaged in obese people ... to new research from the University of Adelaide . ... who lose weight on a diet eventually put that weight back ... Kentish investigated the impact of a high-fat diet on the gut,s ...
... YORK , Sept. 16, 2013 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Dry Eye Syndrome - India ...
Cached Biology News:Specific sugar molecule causes growth of cancer cells 2Obese stomachs tell us diets are doomed to fail 2PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022 4
Vented Caps for 75 cm2 Flasks...
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
BD BioCoat Laminin 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
... Series 4000 incorporates the critical design features ... in biomarker research. The Series 4000 delivers ... converting biomarker discoveries to biomarker assays all ... is designed to fit into the research ...
Biology Products: